These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25772456)

  • 1. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
    Siddiqi T; Rosen ST
    Oncology (Williston Park); 2015 Apr; 29(4):299-308. PubMed ID: 25920929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Bello C; Veliz M; Pinilla-Ibarz J
    Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation cancer biologics shine in studies.
    Dalzell MD
    Manag Care; 2013 Oct; 22(10):58-9. PubMed ID: 24350384
    [No Abstract]   [Full Text] [Related]  

  • 5. The era of immuno-oncology: are we there yet?
    Villasboas JC; Ansell SM
    Oncology (Williston Park); 2015 Mar; 29(3):204-5. PubMed ID: 25772457
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.
    Cheson BD; Wendtner CM; Pieper A; Dreyling M; Friedberg J; Hoelzer D; Moreau P; Gribben J; Knop S; Montillo M; Rummel M
    Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):21-7. PubMed ID: 20223726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C; Castillo J
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
    Pongas G; Cheson BD
    Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of monoclonal antibodies for the treatment of hematological malignancies.
    Migkou M; Dimopoulos MA; Gavriatopoulou M; Terpos E
    Expert Opin Biol Ther; 2009 Feb; 9(2):207-20. PubMed ID: 19236251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Pawelski S
    Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical use of monoclonal antibodies in malignant lymphomas].
    Schnell R; Hiddemann W; Diehl V; Engert A
    Internist (Berl); 2001 Jun; 42(6):815-6, 819-26. PubMed ID: 11449628
    [No Abstract]   [Full Text] [Related]  

  • 15. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
    Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutropenia in patients treated with rituximab.
    Voog E; Morschhauser F; Solal-Céligny P
    N Engl J Med; 2003 Jun; 348(26):2691-4; discussion 2691-4. PubMed ID: 12826650
    [No Abstract]   [Full Text] [Related]  

  • 20. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
    Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
    Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.